普拉克索与多巴丝肼治疗帕金森病的成本效果分析

目的 比较单用多巴丝肼与合用普拉克索治疗帕金森病两种方法效果.方法 采用对照研究方法,比较多巴丝肼治疗组(A组)及合用普拉克索治疗组(B组)的治疗效果及治疗成本.结果 B组虽然在药物费用及治疗费用方面较A组明显增加(P＜0.01),但其帕金森病综合量表评分显著下降(P＜0.05),而且在帕金森病各期均可应用.结论 联合应用普拉克索虽会加重药物成本及治疗成本,但在改善帕金森病各期临床症状方面效果更好,且可应用于不同分期的帕金森病患者,应个体化推荐.

Cost-effectiveness aralysis of pramipexole combined with levodopa/benserazide in the hospitalized Parkinson's disease patients

Objective To assess cost-effectiveness of pramipexole and levodopa/benserazide in the hospital- ized Parkinson＇s disease （PD） patient. Methods 81 PD patients were divided into group A （levodopa/benserazide group） and group B （pramipexole combined with levodopa/benserazide group） according to different pharmacotherapy. The curative effects and costs of hospitalized PD patients were evaluated. The curative effects were evaluated by unified Parkinson＇s disease rating scale （UPDRS）. Results There were 44 patients in group A and 37 patients in group B. Although B group in drug costs and treatment costs were increased more significantly than A group （ P 〈 0. 01 ） ,but declined markedly UPDRS after treatment （P 〈 0.05 ） than A group. Pramipexole can be applied in all kinds of Hoehn and Yahr states in PD. Conclusion Although the combination of pramipexole would increase drug costs and treatment costs, but could improve the clinical symptoms of PD, and can be applied to different stages of PD. It should be individualized recommendation in the Parkinson＇s patients.